Curis Doses First Patient in Phase 1 Study of CA-4948 in Combination with Ibrutinib in Patients with Relapsed or Refractory Hematologic Malignancies

Author's Avatar
Feb 09, 2021
Article's Main Image

- Amends existing protocol of ongoing Phase 1 study in R/R NHL -

- Initial data expected in the fourth quarter of 2021 -

PR Newswire